LONDON, April 3, 2013 /PRNewswire/ --
Major pharmaceutical companies such as Zoetis Inc. (NYSE: ZTS) and Novartis AG (NYSE: NVS) have been facing increasing competition from generic drugs. Recently, Novartis lost a major patent case in India for its cancer drug. With patents on several blockbuster drugs scheduled to expire in 2013, competition from generic drugs is expected to increase. The key for major drug manufacturers will be to boost their product pipeline. Another major trend in the healthcare sector has been the Affordable Care Act (ACA), which was upheld by the Supreme Court last year. The ACA is expected to have a significant impact on major drug manufacturers as well as on biotechnology companies such as Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Orexigen Therapeutics Inc. (NASDAQ: OREX). On Tuesday, shares of all companies except Novartis AG ended lower even as the broad market posted gains. StockCall has posted free technical research reports on NVS, OREX, ZTS, and NVS and these can be accessed by signing up at
Novartis AG shares touched a 52-week high of $71.75 in trading on Tuesday. The stock ended the day 0.37% higher at $71.32, taking its gains in the last three trading sessions to over 1.20%. Shares of NVS have had an excellent run this year, gaining nearly 17%, compared to a gain of a little over 10% for the S&P 500. The stock has seen a series of highs over the past few months, which is a bullish signal. Download the free report on NVS upon registration at
Shares of Zoetis Inc. ended marginally lower in Tuesday's trading session. The stock finished the day 0.12% lower at $32.55. Earlier in the day, Zoetis' shares had risen to a high of $33.13. However, the stock failed to hold on to its momentum. The company's shares have gained nearly 5% since the stock began trading in February this year. The stock has an all-time high of $35.42. Its MACD chart is currently giving bearish signals. ZTS technical report can be accessed for free by signing up at
Shares of Orexigen Therapeutics Inc. fell sharply in trading yesterday. The stock fell to an intra-day low of $6.04 before finishing the day 1.14% lower at $6.09. Despite the pullback on Tuesday, Orexigen's shares have gained 3.75% in the last three sessions. The company's shares are currently facing stiff resistance at around $6.60. The stock is currently trading well above its 50-day and 200-day moving averages, which is a bullish signal. Shares of OREX have outperformed the broad market so far in 2013, gaining 16%. The free report on OREX can be downloaded by signing up now at
Shares of Teva Pharmaceutical Industries Ltd. fell in trading on Tuesday; however, the losses were limited. The stock ended the day 0.05% lower at $39.55 after touching an intra-day low of $39.43. Teva's shares have had a decent run in 2013 so far. Year-to-date, the stock has gained nearly 6.80%. The stock had rallied at the beginning of March, however, it saw a sharp pullback after failing to break through $41 resistance level. The stock's MACD is currently trading below the signal line, which is a bearish signal. Free report on TEVA can be accessed by registering at
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here